Category Archives: Cell Therapy

Stem Cell Injection Treatment Stem Cell Therapy
Salah satu kaedah perawatan menggunakan Sel Induk dari Tulan Belakang.. Untuk maklumat lanjut boleh call/WA/Telegram/SMS ke 013-3530172 atau layarai web http://www.cellmaxx4all.com.

By: KAMARUZAMAN DERAMAN

Follow this link:
Stem Cell Injection Treatment Stem Cell Therapy - Video

Durham, NC (PRWEB) March 19, 2015

A new study appearing in STEM CELLS Translational Medicine has moved science one step closer to finding a simple treatment for erectile dysfunction (ED) after prostate cancer surgery, eschewing the usual pharmaceutical drug route with potential for harmful side effects, in favor of stem cell therapy that can help the body regenerate.

The study, conducted in rats, compares the effectiveness of using a byproduct of liposuction uncultured stromal vascular fraction (SVF) with adipose-derived stem cells (ADSCs) cultured in the lab to treat ED caused by injury to the cavernous nerve (CN). This nerve, which facilities erection, is sometimes injured during a radical prostatectomy to treat prostate cancer.

ADSCs are harvested from fat and are an attractive source of stem cells for several reasons: They are abundant and can be easily obtained using minimally invasive liposuction. Also, they have characteristics similar to bone marrow-derived stem cells in terms of self-renewal and multipotency. Furthermore, ADSCs retain their ability to divide and grow longer than bone marrow-derived stem cells, which may be beneficial in treating chronic conditions.

On the other hand, cultured ADSCs have limitations, including the cost and time of culturing them, the potential for contamination, changes in cell characteristics during culturing procedures, and their tendency to sometimes form tumors. To avoid these risks, uncultured SVF has emerged as an easier and safer way to use stem and progenitor cells (which are further along in the differentiation process) derived from adipose tissue. SVF comes from the disposable byproduct of liposuction.

However, no study had yet reported side-by-side comparisons of uncultured SVF and cultured ADSCs in treating ED. That was the objective of this study, led by Dalsan You, M.D., Ph.D., and Choung-Soo Kim, M.D., Ph.D., and their colleagues at the Asan Medical Center and University of Ulsan College of Medicine in Seoul, Korea. They tested the cells using 40 rats with and without injured CNs. One group of animals was injected with cultured ADSCs; one received uncultured SVF, and a control group received no stem cells. Four weeks later, both sources of stem cells had significantly improved the animals erection function over the control group. Also, both stem cell types significantly increased the number of nNOS-positive nerve fibers, suggesting that they stimulated nerve regeneration.

However, Dr. Kim said, the cells coming from uncultured SVF outperformed the cultured ADSCs in terms of smooth muscle/collagen ratio and endothelial cell content in the blood vessels, which are also important factors in repairing ED.

Further research is now ongoing to determine the optimal protocol for cellular therapy of ED following CN injury, Dr. You added. We want to follow the progress of the animals over the long term and also we want to see what happens with multiple stem cell injections, rather than just the one given in this study.

This first study to compare two types of cells derived from fat tissue in a rat model of erectile dysfunction after prostate cancer surgery is an important step in identifying effective new treatments for this condition, said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

###

See the original post here:
Study Shows Liposuction Byproduct Could Lead to ED Cure

Stem Cell Therapy- Sci Video2
Created using PowToon -- Free sign up at http://www.powtoon.com/join -- Create animated videos and animated presentations for free. PowToon is a free tool...

By: Georgia McDonald

See the original post:
Stem Cell Therapy- Sci Video2 - Video

BOSTON (TheStreet) --A question about Neuralstem (CUR - Get Report) and its stem-cell therapy for ALS kicks off this week's Biotech Stock Mailbag.

Steve writes, "If 47% of the people responded well and their progression of the disease slowed considerably, then I see this as a huge success for a disease with no cure. I don't have ALS or know anyone that does, but if I had it, I would immediately want the treatment knowing that there is a 47% chance that I will respond positively to it and it would DRASTICALLY slow the progression of the disease. Wouldn't you agree, or am I missing the point somewhere?"

Eight of the 15 (53%) ALS patients enrolled in the study saw their ALSFRS scores fall from an average of 40 to 14 over nine months. This is a rapid decline in muscle function and suggests NSI-566 accelerates the progression of ALS.

If you believe 47% of patients in the Neuralstem study benefit from NSI-566, you can't ignore the 53% of patients who fare far worse and may actually be harmed by the stem cell therapy.

Read the original:
Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin